Dear All,
In the past we used to think Modeling and Simulation is for computer geeks in R&D and interesting. Not anymore, now M&S is used for regulatory approvals and labeling. Always seeing a live example as how it is done and see where else M&S has been to reduce clinical costs is always exciting. Bottom line for any industry is R&D cost minimization with faster approvals.
AAPS RS community keeps an eye on what is innovative and helps pharmaceutical drug development. Two well known scientists in the area of PBPK Modeling are going to speak about how PBPK Modeling has helped approvals at the FDA or expected to help acceptable drug development.
Anyone that use M&S in clinical/nonclinical drug development will benefit from this session. Nice educational material for students also.
If you are around at the PharmSci 360 in Boston, come and join us.
-Raja
Session Detail:
Hot Topic: PBPK modeling: Exponentially Expanding Science
Wednesday, October 19, 2022, Room 153 A, 9:00 AM – 10:00 AM
Moderator: Raja Velagapudi, PhD
Sr. Dir., Clinical Development, Tolmar Inc.
9:00 – 9:30 am Speaker: Heidi J. Einolf, Ph.D.
Exec. Dir., Modeling & Simulation, Novartis
Scemblix: Use of PBPK Models In Lieu of Clinical Trials
9:30 am – 10:00 am Speaker: Hannah M. Jones, Ph.D.
SVP, Head of PBPK Consulting, Simcyp, Certara
Applications and Regulatory Acceptance of PBPK Modeling
------------------------------
Raja Velagapudi Ph.D.
Sr. Director, Clinical Development
Tolmar Inc
Monmouth Junction NJ
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------